World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
93
Citations
34184
World Ranking
10825
National Ranking
1032

Overview

John Radford is affiliated with the University of Manchester in the United Kingdom. Their research primarily spans the field of Medicine, with a focus on several critical subfields including Pathology and Forensic Medicine, Oncology, Pulmonary and Respiratory Medicine, Genetics, and Radiology, Nuclear Medicine and Imaging.

Their work extensively covers topics related to Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Lung Cancer Treatments and Mutations, CAR-T cell therapy research, CNS Lymphoma Diagnosis and Treatment, Viral-associated cancers and disorders, and Monoclonal and Polyclonal Antibodies Research.

Frequent co-authors contributing regularly to their research include:

  • Pier Luigi Zinzani
  • Kirit M. Ardeshna
  • Mehdi Hamadani
  • Brian T. Hess
  • Ranjana H. Advani

Their publications appear predominantly in the following venues:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Hematological Oncology
  • HemaSphere
  • Journal of Clinical Oncology

Some recent notable papers authored or co-authored by Radford include:

  • Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial, 2020, The Lancet Oncology
  • Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial, 2021, The Lancet Oncology
  • Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma, 2022, New England Journal of Medicine
  • Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma, 2020, Blood
  • Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial, 2021, The Lancet Haematology

Best Publications

  • Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

    Michael L. Wang;Simon Rule;Peter Martin;Andre Goy

  • Rituximab (Anti-CD20 Monoclonal Antibody) for the Treatment of Patients With Relapsing or Refractory Aggressive Lymphoma: A Multicenter Phase II Study

    B. Coiffier;C. Haioun;N. Ketterer;A. Engert

  • Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

    Robert Chen;Pier Luigi Zinzani;Michelle A. Fanale;Philippe Armand

  • Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma

    Peter Johnson;Massimo Federico;Amy A Kirkwood;Alexander Fossa

  • Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.

    John Radford;Tim Illidge;Nicholas Counsell;Barry Hancock

  • Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

    Joseph M. Connors;Wojciech Jurczak;David J. Straus;Stephen M. Ansell

  • European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic Lymphoma

    James M. Foran;Ama Z. S. Rohatiner;David Cunningham;Razvan A. Popescu

  • Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

    David Cunningham;Eliza A Hawkes;Andrew Jack;Wendi Qian

  • Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.

    J Verweij;A van Oosterom;J.-Y Blay;I Judson

  • Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial

    Ruth Pettengell;Howard Gurney;John A Radford;David P Deakin

  • Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma

    Franck Morschhauser;John Radford;Achiel Van Hoof;Umberto Vitolo

  • Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial

    A. Le Cesne;J.Y. Blay;I. Judson;A. Van Oosterom

  • Myocardial Infarction Mortality Risk After Treatment for Hodgkin Disease: A Collaborative British Cohort Study

    Anthony J. Swerdlow;Craig D. Higgins;Paul Smith;David Cunningham

  • Orthotopic reimplantation of cryopreserved ovarian cortical strips after high-dose chemotherapy for Hodgkin's lymphoma

    John A Radford;B A Lieberman;Daniel R Brison;A R Smith

  • Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma : a study by the EORTC Soft Tissue and Bone Sarcoma Group

    Ian R Judson;John A Radford;Maggie A Harris;Jean-Yves Blay

  • Multicenter phase II study of iodine-131 tositumomab for chemotherapy- relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas

    Julie Marie Vose;Richard L. Wahl;Mansoor Saleh;Ama Z. Rohatiner

  • How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines

    H. G. Laverty;C. Benson;E. J. Cartwright;M. J. Cross

  • Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.

    Michael L. Wang;Kristie A. Blum;Peter Martin;Andre Goy

  • Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.

    Franck Morschhauser;Hervé Tilly;Aristeidis Chaidos;Pamela McKay

  • Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma

    Sally F. Barrington;Wendi Qian;Edward J. Somer;Antonella Franceschetto

Frequent Co-Authors

Peter Johnson
Peter Johnson University of Southampton
David Cunningham
David Cunningham Royal Marsden NHS Foundation Trust
Pier Luigi Zinzani
Pier Luigi Zinzani University of Bologna
Gilles Salles
Gilles Salles Memorial Sloan Kettering Cancer Center
David C. Linch
David C. Linch University College London
Craig H. Moskowitz
Craig H. Moskowitz University of Miami
Nick Thatcher
Nick Thatcher University of Manchester
Peter Hoskin
Peter Hoskin University of Manchester
Massimo Federico
Massimo Federico University of Modena and Reggio Emilia
Caroline Dive
Caroline Dive University of Manchester

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a medical career in the USA opens up a wide range of academic and professional options, especially for those seeking flexible and affordable education. Many students choose online pathways to accelerate or streamline their healthcare careers.

For working nurses aiming to advance, the cheapest dnp programs online allow for doctoral study without the high financial burden of traditional programs. Similarly, those holding a registered nurse license may want to consider what is the cheapest rn to bsn program online to quickly complete their bachelor’s degree at an affordable cost.

If you're coming from a non-nursing background but aspire to advanced practice roles, direct entry np programs for non nurses online offer a fast track into nurse practitioner careers. For those just beginning, researching the easiest rn program to get into can increase your chances of admission and save valuable time.

With the increasing availability of online programs, pursuing a health-related degree is more accessible than ever and can help launch or advance your medical career in the USA.

Best Scientists Citing John Radford

Trending Scientists

Recently Published Articles